CN108883108B - 马赛替尼用于治疗肌萎缩侧索硬化症患者亚群的用途 - Google Patents

马赛替尼用于治疗肌萎缩侧索硬化症患者亚群的用途 Download PDF

Info

Publication number
CN108883108B
CN108883108B CN201780019760.9A CN201780019760A CN108883108B CN 108883108 B CN108883108 B CN 108883108B CN 201780019760 A CN201780019760 A CN 201780019760A CN 108883108 B CN108883108 B CN 108883108B
Authority
CN
China
Prior art keywords
masitinib
als
pharmaceutically acceptable
acceptable salt
alsfrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780019760.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN108883108A (zh
Inventor
阿兰·穆塞
珍-皮埃尔·基内特
科林·曼斯菲尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AB Science SA
Original Assignee
AB Science SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AB Science SA filed Critical AB Science SA
Publication of CN108883108A publication Critical patent/CN108883108A/zh
Application granted granted Critical
Publication of CN108883108B publication Critical patent/CN108883108B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780019760.9A 2016-03-25 2017-03-24 马赛替尼用于治疗肌萎缩侧索硬化症患者亚群的用途 Active CN108883108B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16162490 2016-03-25
EP16162490.3 2016-03-25
PCT/EP2017/057134 WO2017162884A1 (en) 2016-03-25 2017-03-24 Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation

Publications (2)

Publication Number Publication Date
CN108883108A CN108883108A (zh) 2018-11-23
CN108883108B true CN108883108B (zh) 2021-08-06

Family

ID=55637258

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780019760.9A Active CN108883108B (zh) 2016-03-25 2017-03-24 马赛替尼用于治疗肌萎缩侧索硬化症患者亚群的用途

Country Status (20)

Country Link
US (1) US10092564B2 (https=)
EP (1) EP3240538B1 (https=)
JP (2) JP7250312B2 (https=)
KR (1) KR102293847B1 (https=)
CN (1) CN108883108B (https=)
AU (1) AU2017236177B2 (https=)
BR (1) BR112018069515A2 (https=)
CA (1) CA3018635C (https=)
DK (1) DK3240538T3 (https=)
EA (1) EA038531B1 (https=)
ES (1) ES2899929T3 (https=)
HU (1) HUE057398T2 (https=)
IL (1) IL261856B (https=)
MX (1) MX390495B (https=)
NZ (1) NZ745778A (https=)
PL (1) PL3240538T3 (https=)
PT (1) PT3240538T (https=)
SG (1) SG11201808106YA (https=)
SI (1) SI3240538T1 (https=)
WO (1) WO2017162884A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3563849A3 (en) 2012-10-25 2020-02-12 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CN110305095A (zh) 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア
DK3425390T3 (da) 2016-11-25 2021-02-15 Genuv Inc Sammensætning til fremme af differentiering og beskyttelse af neurale stamceller og fremgangsmåde til induktion af neural regenerering ved anvendelse heraf
MX394840B (es) * 2017-03-28 2025-03-24 Novartis Ag Nuevos metodos para el tratamiento de la esclerosis multiple.
MY205552A (en) * 2017-05-30 2024-10-25 Deciphera Pharmaceuticals Inc Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl ]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha
US11692029B2 (en) 2018-03-05 2023-07-04 The Schepens Eye Research Institute, Inc. Therapy for glaucoma and optic neuropathy by targeting colony stimulating factors
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
MX2021006869A (es) 2018-12-10 2021-07-02 Massachusetts Gen Hospital Esteres de cromolin y usos de los mismos.
CN112618717A (zh) * 2019-09-24 2021-04-09 北京大学深圳研究生院 Btk抑制剂用于治疗肌萎缩侧索硬化症的用途
EP4084779B1 (en) * 2019-12-30 2024-10-09 Deciphera Pharmaceuticals, LLC Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
WO2022146914A1 (en) 2020-12-28 2022-07-07 The General Hospital Corporation Cromolyn derivatives and uses thereof
WO2025113494A1 (zh) * 2023-11-27 2025-06-05 浙江径科医药有限公司 多环类化合物及其应用
WO2026015576A1 (en) * 2024-07-09 2026-01-15 PhenoNet, Inc. Methods and systems for treatment of neurodegenerative disease and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014145909A2 (en) * 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
WO2015063318A1 (en) * 2013-11-04 2015-05-07 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis
CN104968347A (zh) * 2012-10-04 2015-10-07 Ab科学有限公司 马赛替尼用于治疗使用预测因素鉴别的患者亚群的癌症的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (https=) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
US8153792B2 (en) 2007-02-13 2012-04-10 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
US8906357B2 (en) 2010-04-20 2014-12-09 Ab Science Treatment of multiple sclerosis with masitinib
BR112014000742A2 (pt) 2011-07-13 2016-08-23 Andrew A Wolff terapia de combinação de als

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104968347A (zh) * 2012-10-04 2015-10-07 Ab科学有限公司 马赛替尼用于治疗使用预测因素鉴别的患者亚群的癌症的用途
WO2014145909A2 (en) * 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
WO2015063318A1 (en) * 2013-11-04 2015-05-07 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
c-Abl Inhibition Delays Motor Neuron Degeneration in the G93A Mouse, an Animal Model of Amyotrophic Lateral Sclerosis;Ryu Katsumata et al;《Plos one》;20120925;第7卷(第9期);全文 *
TherapeuticDevelopmentinAmyotrophicLateralSclerosis;Monica Bucchia,MS et al;《Clinical Therapeutics》;20141229;第37卷(第3期);全文 *

Also Published As

Publication number Publication date
SG11201808106YA (en) 2018-10-30
MX2018011349A (es) 2019-02-07
WO2017162884A1 (en) 2017-09-28
IL261856A (en) 2018-10-31
DK3240538T3 (da) 2021-12-06
BR112018069515A2 (pt) 2019-04-16
JP7250312B2 (ja) 2023-04-03
EA201800499A1 (ru) 2019-03-29
IL261856B (en) 2022-04-01
ES2899929T3 (es) 2022-03-15
AU2017236177A1 (en) 2018-09-20
AU2017236177B2 (en) 2022-03-31
JP2022037132A (ja) 2022-03-08
US20180117037A1 (en) 2018-05-03
PL3240538T3 (pl) 2022-01-31
EP3240538B1 (en) 2021-09-29
SI3240538T1 (sl) 2022-02-28
PT3240538T (pt) 2021-12-07
CA3018635C (en) 2023-09-26
NZ745778A (en) 2022-07-01
MX390495B (es) 2025-03-20
JP2019515884A (ja) 2019-06-13
KR20180125966A (ko) 2018-11-26
HUE057398T2 (hu) 2022-05-28
US10092564B2 (en) 2018-10-09
EA038531B1 (ru) 2021-09-10
EP3240538A1 (en) 2017-11-08
CA3018635A1 (en) 2017-09-28
CN108883108A (zh) 2018-11-23
KR102293847B1 (ko) 2021-08-26

Similar Documents

Publication Publication Date Title
CN108883108B (zh) 马赛替尼用于治疗肌萎缩侧索硬化症患者亚群的用途
ES2824552T3 (es) Método de tratamiento con tradipitant
US9078894B2 (en) Treatment of severe persistant asthma with masitinib
WO2012059526A1 (en) Treatment of mastocytosis with masitinib
RU2672248C1 (ru) Применение производного бензимидазола для лечения ночного кислотного прорыва
JP2020513005A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物
CN106714819A (zh) 治疗普拉德‑威利综合征的方法
US20170119760A1 (en) Use of masitinib for the treatment of progressive supranuclear palsy
US20160263110A1 (en) Use of masitinib for treatment of amyotrophic lateral sclerosis
US7888341B2 (en) Combination of glivec (STI571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer
HK1261581B (zh) 马赛替尼用於治疗肌萎缩侧索硬化症患者亚群的用途
CN115038446A (zh) 马赛替尼治疗嗜酸性粒细胞性哮喘的用途
HK1261581A1 (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
JP2019517516A (ja) Ｓｍａの新規な処置
ES3062815T3 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
TW201924677A (zh) 苯并咪唑衍生物用於夜間酸突破的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261581

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant